华东医药：2024年年度报告（英文版）.PDF

1、Full Text of the 2024 Annual Report of Huadong Medicine Co.,Ltd.1 Huadong Medicine Co.,Ltd.2024 Annual Report April 2025Full Text of the 2024 Annual Report of Huadong Medicine Co.,Ltd.2 A Letter to the Shareholders Distinguished shareholders,Time tempers our original aspiration,and transformation pr

2、opels us forward.As the tides of era surge,we persevere like determined climbers,moving with deliberate persistence and rising with steadfast strides.The year 2024 marked a year of formidable challenges and steady yet significant progress for Huadong Medicine Co.,Ltd.(“Huadong Medicine”,“we”or“the C

3、ompany”).We successfully completed our 7th three-year plan,marked significant strides in innovation and transformation,and advanced our R&D pipelines to the acceptance phase.Moreover,all four of our core business segments achieved accelerated growth,a direct testament to the dedication and persevera

4、nce behind these results.The Company is now operating on a high-quality development trajectory,with revenue and net profit attributable to shareholders having grown by 21.24%and 52.59%respectively since 2021,continually setting new historical records.Our team maintains strategic focus while strength

5、ening foundational capabilities,renewing the Companys vibrant image and driving continuous transformation.As we look back on our journey,each step has been illuminated by innovation,leading to a thriving ecosystem of novel products and solutions.Since 2024,we have achieved successive historic breakt

6、hroughs in innovative product approvals,marked by pioneering industry-first milestones:Elahere,Chinas first FR-targeting ADC for platinum-resistant ovarian cancer,was successfully approved;SAILEXIN emerged as Chinas first biosimilar of Ustekinumab Injection;and the worlds first bedside renal functio